Deals

Merck buys AI drug designs from Isomorphic Labs two days after its $5 billion round

MSD, Merck & Co. (NYSE: MRK) outside the United States and Canada, carries the clinical and commercial risk and pays an undisclosed upfront, milestones and tiered royalties, while Isomorphic Labs holds a new option to co-fund trials for elevated royalties. Two days after the largest life-science venture round ever, the deal hands Alphabet's (Nasdaq: GOOGL) AI drug spinout its fourth Big Pharma payer before any candidate has entered a human trial.

Vincent JiangVincent Jiangthree-minute read
Share
Demis Hassabis, wearing glasses and a dark suit, gestures from a podium bearing the Royal Swedish Academy of Sciences crest
Demis Hassabis, founder and chief executive of Isomorphic Labs and co-founder of Google DeepMind, delivering his Nobel Lecture in Stockholm on December 8, 2024, after sharing the chemistry prize for AlphaFold.

Merck buys designs for an unnamed cancer target

On November 19, Isomorphic Labs$600M — Isomorphic Labs, private, latest valuation $600M, the Google DeepMind spinout led by founder and chief executive Demis Hassabis, winner of the 2024 Nobel Prize in Chemistry for AlphaFold, agreed to discover small-molecule candidates against an oncology target neither company will name, together with MSD, Merck & Co.'s−3.66% — Merck & Co., down 3.66 percent today (NYSE: MRK) trade name outside the United States and Canada 12. Isomorphic runs its IsoDDE drug-design engine over MSD's proprietary data sets and hands back molecular designs; MSD owns everything downstream: preclinical and clinical development, manufacturing and sales 1.

The clinic stays Merck's risk

Money flows toward the lab. Isomorphic takes an undisclosed upfront payment, then research, development, regulatory and commercial milestones, then tiered royalties on net sales 1. The term that carries the story is an option for Isomorphic to co-fund development in return for elevated royalties, noted in passing across the deal's coverage 13. George Addona, who heads discovery, preclinical development and translational medicine at MSD Research Laboratories, cast the pairing as "close coordination of wet-lab and dry-lab functions" 1. Isomorphic sells the designs; Merck buys the risk.

$7.7 billion raised, no valuation given

The option now has a balance sheet behind it. On November 17 Isomorphic closed an oversubscribed $5 billion Series C co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz joining and Alphabet−3.40% — Alphabet, down 3.40 percent today (Nasdaq: GOOGL) investing significantly; the UK BioIndustry Association called it the largest life-science venture raise ever 456.

The money is earmarked for foundational models, the pipeline and clinical-development infrastructure 5. Disclosed funding now stands at $7.7 billion, after $600 million in March 2025 and a $2.1 billion Series B in May 2. The valuation went unsaid; Bloomberg reported a $50 billion ask, on top of the $40 billion or more The Inference reported on October 9 478.

Isomorphic's funding has grown from $0.6 billion to $5 billion a round in 20 months

Each round dwarfed the last, and still no candidate in a human trial

$0bn$2bn$4bn$6bnMar 2025May 2026Nov 2026Two days later, MSD signed
Data
Raised
Mar 2025$0.6bn
May 2026$2.1bn
Nov 2026$5bn
Disclosed external financing, US$ billions: March 2025 first external round led by Thrive Capital, May 2026 Series B, November 2026 Series C co-led by Greenoaks and Sequoia. Sources: Alternatives Watch; Fierce Biotech.2,10

Four of the top eight drugmakers, zero human trials

Merck is the fourth Big Pharma name on the roster, after Eli Lilly−2.19% — Eli Lilly, down 2.19 percent today and Novartis−2.57% — Novartis, down 2.57 percent today signed 2024 alliances worth about $3 billion combined including milestones and Johnson & Johnson−2.09% — Johnson & Johnson, down 2.09 percent today followed this year, a partner list spanning four of the top eight drugmakers by revenue 910. No Isomorphic candidate has entered a human trial; its oncology and immunology results are described only as "positive preclinical", with no named first candidate and no clinical date 4510. The first trial, targeted for end-2026, has already slipped from end-2025 8.

The tell is the option

For Merck holders the cost is an undisclosed line beside an in-house discovery organization; for Alphabet holders the payback on a named AI asset arrives as partner fees and royalties, years before any approved medicine. The number to watch is the one MSD did not disclose, and the move is the one Isomorphic now controls: if it co-funds an MSD trial, the $5 billion 4 stops being a research subsidy and starts buying royalty streams.

Get Deals by email, free

The acquisitions, rounds and contracts that move AI money. In our daily email, every weekday.

Loading GOOGL

Reader comments

0 comments

    Deals

    Salesforce agreed to pay $47.50 a share for Braze, whose SEC-filed FAQ leaves renewal terms undecided

    Three weeks after Salesforce agreed to buy Braze for $5.66 billion, the seller's own SEC-filed sales script promises enterprise buyers nothing beyond today's contracts while its account teams push multi-year renewals. For BRZE holders the stock is now a claim on $47.50 in cash, and the deal documents price the wait.

    Deals

    Musk puts a Tesla-SpaceX merger at 25% within a year

    Prediction-market odds put the announcement in early 2027, and the pay agreement Musk signed in 2025 lets a rich deal price vest shares no operating goal has earned. The cost lands on Tesla holders, who also own the deciding vote.

    Deals

    Sacramento votes to renew Axon for $17.7 million and bar AI training on city camera data

    The renewal makes Sacramento own its camera data, opt out of Axon's AI training and bar default sharing with federal agencies. Spread across renewals, those terms reach the data advantage beneath the software Axon's beaten-down stock now leans on.

    Deals

    AMD closed Taalas at $2.9 billion, with $1.4 billion riding on undisclosed milestones

    AMD's completion release named no price; the quarterly filing that carries the terms makes up to $1.4 billion of the $2.9 billion contingent on conditions the company has not disclosed. It is the second AI acquisition in a fortnight, about $11.1 billion combined, by a stock trading above 100 times trailing earnings.

    Deals

    Cognizant won Network Rail's seven-year data center contract 28% under the buyer's own estimate

    The seven-year data-center award hands Cognizant volume in a weak market, but the buyer's own tender estimate shows a large UK public-sector deal clearing about 28% below budget, and the award notice offers no explanation.

    Deals

    Anthropic IPO nears $500 billion in orders before Nasdaq debut

    Anthropic closed its order books on Tuesday with roughly $400 billion of institutional interest and nearly $100 billion of retail interest, about seven times the shares on offer, and is guiding pricing above its $70–$78 range ahead of Thursday's Nasdaq debut under ANT. The final price lands after the US close tonight, and the money it moves reaches from IPO allocators to the chip and cloud suppliers holding guaranteed Anthropic contracts.

    Subscribe to TheInference for free